GRNA (GreenLight Biosciences Holdings) stock is in for a key growth catalyst

As of close of business last night, GreenLight Biosciences Holdings’s stock clocked out at $0.41, up 21.46% from its previous closing price of $0.34. In other words, the price has increased by $+0.0733 from its previous closing price. On the day, 1237519 shares were traded. GRNA stock price reached its highest trading level at $0.4231 during the session, while it also had its lowest trading level at $0.3170.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



To gain a deeper understanding of GRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.20.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on December 08, 2022, initiated with a Buy rating and assigned the stock a target price of $4.

On October 14, 2022, Credit Suisse started tracking the stock assigning a Outperform rating and target price of $5.50.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 11 when Builders Vision, LLC bought 6,505,102 shares for $3.92 per share. The transaction valued at 25,500,000 led to the insider holds 22,348,123 shares of the business.

Walker Matthew Allen bought 6,377,551 shares of GRNA for $25,000,000 on Aug 11. The Director now owns 22,220,572 shares after completing the transaction at $3.92 per share. On Aug 11, another insider, Morningside Venture Investment, who serves as the 10% Owner of the company, bought 3,061,224 shares for $3.92 each. As a result, the insider paid 11,999,998 and bolstered with 15,919,155 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 16.61 while its Price-to-Book (P/B) ratio in mrq is 0.68.

Stock Price History:

Over the past 52 weeks, GRNA has reached a high of $14.15, while it has fallen to a 52-week low of $0.32. The 50-Day Moving Average of the stock is 0.8422, while the 200-Day Moving Average is calculated to be 2.0974.

Shares Statistics:

It appears that GRNA traded 322.73K shares on average per day over the past three months and 547.32k shares per day over the past ten days. A total of 139.06M shares are outstanding, with a floating share count of 82.54M. Insiders hold about 45.49% of the company’s shares, while institutions hold 25.20% stake in the company. Shares short for GRNA as of Jan 30, 2023 were 2.61M with a Short Ratio of 2.68M, compared to 2.08M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.72% and a Short% of Float of 2.53%.

Earnings Estimates

As of right now, 0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.25 and low estimates of -$0.27.

Analysts are recommending an EPS of between -$1.13 and -$1.3 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$0.89, with 2 analysts recommending between -$0.78 and -$1.